Compare Heron Therapeutics Inc (HRTX) vs Norfolk Southern Corporation (NSC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Norfolk Southern Corporation — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Norfolk Southern Corporation trades at $334.6 (market cap $75.23B). The key difference: Norfolk Southern Corporation is far larger — about 822.5× Heron Therapeutics Inc's market cap, and Norfolk Southern Corporation pays a 1.61% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | NSC | |
|---|---|---|
Market Cap | $91.46M | $75.23B |
Sector | Health | Technology |
52-Week High | $1.96 | $340.16 |
52-Week Low | $0.39 | $272.35 |
Enterprise Value | $189.36M | $90.99B |
Dividend Yield | — | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Norfolk Southern (NSC) trades at $334.97, down 1.53% today, with a bullish technical outlook from moving averages but overbought RSI signals. The company shows strong profitability with a 21.91% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights the pending merger with Union Pacific and upcoming Q2 2026 earnings on July 23, 2026.
The stock offers a moderate upside to the $344.40 consensus price target, supported by earnings momentum and cost controls, but faces risks from regulatory scrutiny of the merger and rich valuations. Investor sentiment is mixed amid merger uncertainties and high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →
